Phase 2 Myasthenia Gravis Trial, Recruiting NCT06414954 Sponsor: NMD Pharma A/S Condition: Myasthenia Gravis
Back to Myasthenia Gravis

Phase 2 Myasthenia Gravis Trial, Recruiting

NCT06414954
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a man or woman aged 18 or older at the time of signing the consent form
  • You have been diagnosed with Myasthenia Gravis (MG) at a moderate to severe level (classified as MGFA class II, III, or IV)
  • You have had a blood test that confirmed the presence of specific antibodies linked to MG (called AChR or MuSK antibodies)
  • You are able to swallow tablets
  • Your body weight and height fall within a healthy range (BMI between 18 and 35), and you weigh at least 40 kg (about 88 lbs)
  • You are willing and able to use an appropriate method of contraception during the study, as required by local guidelines
  • You are able to understand the study and have given your signed agreement to take part

Who may not be able to join:

  • You have a known physical or mental health condition that, in the doctor's opinion, could affect your safe participation or make it harder to assess the results
  • You have other significant health or lab test findings that could interfere with how the study is run or its results
  • You have taken part in another clinical trial or received an experimental treatment within the past 30 days (or longer, depending on the medication involved)
  • You have a history of not following or sticking to your MG treatment as prescribed
  • You are currently pregnant, breastfeeding, or planning to become pregnant during the study (for female participants)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: contact@nmdpharma.com

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
NMD Pharma A/S
Registry
ClinicalTrials.gov
Start date
16 May 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇧🇪 Belgium 🇩🇰 Denmark 🇫🇷 France 🇬🇪 Georgia 🇮🇹 Italy 🇳🇱 Netherlands 🇵🇱 Poland 🇷🇸 Serbia 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Change from baseline to day 21 in QMG total score for NMD670 vs placebo

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov